Catalent
Catalent and Galapagos Collaborate on Decentralized CAR-T Manufacturing; Kindeva Secures $129M Contract for Nerve Agent Antidote
Catalent, Galapagos, CAR-T therapy, Decentralized manufacturing, Non-Hodgkin lymphoma (NHL), Kindeva Drug Delivery, DuoDote, Nerve agent antidote, Strategic National Stockpile
Novo Holdings to Finalize $16.5B Acquisition of Catalent Following Regulatory Clearance
Novo Holdings, Catalent, Acquisition, Regulatory Clearance, Life Sciences, Pharmaceutical Development
European Commission Approves Novo Holdings’ $16.5B Acquisition of Catalent
Novo Holdings, Catalent, European Commission, Acquisition, Pharmaceutical Industry
Novo Holdings Receives Unconditional EU Approval for $16.5 Billion Acquisition of Catalent
Novo Holdings, Catalent, European Commission, Acquisition, EU Approval, Pharmaceutical Services
Catalent Misses Revenue Estimates Amid Growing Opposition to Novo Holdings’ $16.5 Billion Acquisition
Catalent, Novo Holdings, Acquisition, Revenue Estimates, Pharmaceutical Market, Competition, FTC, Antitrust
Catalent Falls Short of Q1 Revenue Projections Amid Growing Opposition to Novo Holdings’ $16.5 Billion Acquisition
Catalent, Q1 Revenue, Novo Holdings, Acquisition, Pharmaceutical Industry, Contract Manufacturing
EU Regulators Schedule December 6 Decision on Novo Holdings’ Acquisition of Catalent
EU regulators, Novo Holdings, Catalent, acquisition, antitrust review, December 6 deadline
Roche CEO Urges Antitrust Regulators to Block Novo Holdings’ Acquisition of Catalent
Novo Holdings, Catalent, Roche, Antitrust Regulators, Pharmaceutical Industry, Mergers and Acquisitions
Catalent Sells New Jersey Facility and HQ to Ardena, Expanding Belgian CDMO’s US Footprint
Catalent, Ardena, New Jersey manufacturing plant, HQ sale, CDMO expansion, pharmaceutical manufacturing
Catalent Reports Strong Q4 Results Amid Pending Acquisition by Novo Holdings
Catalent, Q4 Results, Novo Holdings, Acquisition, Pharmaceutical, Biotech, Consumer Health